| Secondary |
| Drug Use For Unknown Indication |
37.5% |
| Hyperemesis Gravidarum |
22.1% |
| Analgesic Therapy |
8.8% |
| Pain |
7.4% |
| Product Used For Unknown Indication |
7.4% |
| Abdominal Discomfort |
2.9% |
| Procedural Pain |
2.9% |
| Analgesia |
1.5% |
| Medical Diet |
1.5% |
| Vitamin Supplementation |
1.5% |
| Arthralgia |
0.7% |
| Asthma |
0.7% |
| Blood Cholesterol Increased |
0.7% |
| Chronic Fatigue Syndrome |
0.7% |
| Fluid Retention |
0.7% |
| Irritable Bowel Syndrome |
0.7% |
| Multiple Sclerosis |
0.7% |
| Sleep Disorder |
0.7% |
| Vitamin B12 Deficiency |
0.7% |
|
| Maternal Exposure During Pregnancy |
20.8% |
| Post Procedural Haemorrhage |
16.7% |
| Kidney Malformation |
12.5% |
| Drug Interaction |
8.3% |
| Mania |
8.3% |
| Congenital Anomaly |
4.2% |
| Haemorrhage |
4.2% |
| International Normalised Ratio Abnormal |
4.2% |
| Normal Newborn |
4.2% |
| Rash |
4.2% |
| Rhabdomyolysis |
4.2% |
| Sinus Tachycardia |
4.2% |
| Vitamin B12 Deficiency |
4.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
25.8% |
| Product Used For Unknown Indication |
22.4% |
| Maternal Exposure During Pregnancy |
7.2% |
| Nausea |
6.9% |
| Prophylaxis |
3.8% |
| Osteopenia |
3.4% |
| Premedication |
3.4% |
| Breast Cancer |
3.1% |
| Pain |
2.9% |
| Hypertension |
2.8% |
| Supplementation Therapy |
2.4% |
| Diabetes Mellitus |
2.2% |
| Prophylaxis Of Nausea And Vomiting |
2.2% |
| Vitamin Supplementation |
2.2% |
| Anxiety |
1.7% |
| Osteoporosis |
1.7% |
| Gastrooesophageal Reflux Disease |
1.5% |
| Asthma |
1.4% |
| Hypothyroidism |
1.4% |
| Infection Prophylaxis |
1.4% |
|
| Vesicoureteric Reflux |
12.2% |
| Vomiting |
11.0% |
| Nausea |
9.8% |
| White Blood Cell Count Increased |
7.3% |
| Sepsis |
6.1% |
| Visual Acuity Reduced |
6.1% |
| Flushing |
4.9% |
| Headache |
3.7% |
| Hypomagnesaemia |
3.7% |
| Kidney Malformation |
3.7% |
| Neutropenia |
3.7% |
| Pain In Extremity |
3.7% |
| Rhabdomyolysis |
3.7% |
| Tinnitus |
3.7% |
| Vertigo Labyrinthine |
3.7% |
| Vision Blurred |
3.7% |
| Actinic Keratosis |
2.4% |
| Cardiac Disorder |
2.4% |
| Drug Ineffective |
2.4% |
| Dyspnoea |
2.4% |
|
| Interacting |
| Analgesic Therapy |
33.3% |
| Arthritis |
33.3% |
| Chronic Myeloid Leukaemia |
16.7% |
| Smoking Cessation Therapy |
16.7% |
|
| Anaphylactic Shock |
40.0% |
| Hepatotoxicity |
20.0% |
| Post Procedural Haemorrhage |
20.0% |
| Thinking Abnormal |
20.0% |
|
